These results suggest that targeting PLK1 alone or in combination with BRAF inhibitors may serve as a novel therapeutic option in melanomas, particularly in melanomas with a BRAFV600E mutation in which resistance to BRAFi has developed. This evidence concerns the gene BRAF and melanoma.